NEW LAUNCH: CarciVac®, vaccine onco BCG

28/09/2020

Bioprofarma Bagó presents CarciVac® for the treatment of non-muscle invasive bladder cancer. We are pleased to announce the launch of CarciVac® vaccine onco BCG Bacilo Calmette-Guérin. This product complements our Urology portfolio continuing our commitment to patients suffering bladder cancer.

CarciVac® is manufactured by Serum Institute of India, the world’s largest producer of vaccines, which allows us to guarantee the availability of the product in the market.

CarciVac® vaccine onco BCG Bacilo Calmette-Guérin is indicated for the treatment of:

  • Flat urothelial cell carcinoma in situ (CIS) of the bladder
  • As adjuvant treatment after TUR of primary or recurrent superficial papillary urothelial cell carcinoma (stage Ta and T1).

It is presented in a 40 mg lyophilized ampoule bottle for 3 vials.

For more information, please click here

 

(Español) Día Mundial de la Lucha contra el Cáncer de Mama

(Español) Desde Bioprofarma Bagó nos queremos sumar a la concientización en el Día Mundial de la Lucha contra el Cáncer de Mama

Lymphomas Cutaneous Conference

We´ve participated in the lymphomas cutaneous conference organized by the Argentine Society of Dermatology.